Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15445MR)

This product GTTS-WQ15445MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15445MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4009MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ13423MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ11538MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ5341MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ803MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ7650MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ5776MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ13201MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04950615
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW